6. Stock-Based Compensation

The compensation costs that have been charged against income for the thirteen weeks and thirty-nine weeks ended November 3, 2018 and October 28, 2017 were as follows (in thousands):

	Thirteen Weeks Ended				Thirty-Nine Weeks Ended
	November 3, 2018		October 28, 2017		November 3, 2018		October 28, 2017
Stock-based compensation expense by type:
Stock options	$	8	$	8	$	185	$	181
Restricted stock units		702		796		3,074		2,905
Employee stock purchases		24		19		81		75
Director deferred compensation		24		6		71		18
Total stock-based compensation expense		758		829		3,411		3,179
Income tax benefit recognized		172		305		762		1,151
Stock-based compensation expense, net of income tax	$	586	$	524	$	2,649	$	2,028

In the thirteen weeks and thirty-nine weeks ended November 3, 2018 and October 28, 2017, we granted the following equity awards:

	Thirteen Weeks Ended				Thirty-Nine Weeks Ended
	November 3, 2018		October 28, 2017		November 3, 2018		October 28, 2017
Stock options		-		18,577		19,994		38,949
Restricted stock unit awards		-		-		169,572		108,429
Performance-based restricted stock unit awards		-		-		44,700		54,900
Deferred stock units		1,247		417		3,249		904

At November 3, 2018, the total compensation costs related to nonvested restricted stock unit awards not yet recognized was $5.7 million and the weighted-average period over which such awards are expected to be recognized was 3.0 years. There were no compensation costs related to nonvested stock options at November 3, 2018.

Under the 2012 Non-Employee Director Equity Plan (2012 Plan), a total of 4,435 and 3,361 shares of our common stock were awarded during the thirty-nine weeks ended November 3, 2018 and October 28, 2017, respectively, as part of the annual equity award to directors in the first quarter.

The weighted-average grant date fair value of stock options granted during the thirty-nine weeks ended November 3, 2018 was $7.15. The weighted-average grant date fair value of stock options granted during the thirteen and thirty-nine weeks ended October 28, 2017 was $4.20 and $6.20 per share, respectively.

The number of shares purchased, the average price per share and the weighted-average grant date fair value of shares purchased through our employee stock purchase plan were as follows:

	Thirteen Weeks Ended				Thirty-Nine Weeks Ended
	November 3, 2018		October 28, 2017		November 3, 2018		October 28, 2017
Shares purchased		6,029		6,239		18,360		16,984
Average price per share	$	15.98	$	12.11	$	17.56	$	18.00
Weighted average fair value at grant date	$	5.10	$	4.52	$	4.97	$	4.43